HRP20131083T1 - POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI - Google Patents

POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI Download PDF

Info

Publication number
HRP20131083T1
HRP20131083T1 HRP20131083AT HRP20131083T HRP20131083T1 HR P20131083 T1 HRP20131083 T1 HR P20131083T1 HR P20131083A T HRP20131083A T HR P20131083AT HR P20131083 T HRP20131083 T HR P20131083T HR P20131083 T1 HRP20131083 T1 HR P20131083T1
Authority
HR
Croatia
Prior art keywords
compound
prepared
accordance
intended
administration
Prior art date
Application number
HRP20131083AT
Other languages
English (en)
Croatian (hr)
Inventor
Joyce K. James
Shawn R. Eichelberger
Traci L. Savall
Original Assignee
Ambit Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corporation filed Critical Ambit Biosciences Corporation
Publication of HRP20131083T1 publication Critical patent/HRP20131083T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HRP20131083AT 2007-11-08 2008-11-07 POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI HRP20131083T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US580307P 2007-12-07 2007-12-07
US9867608P 2008-09-19 2008-09-19
US11206008P 2008-11-06 2008-11-06
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Publications (1)

Publication Number Publication Date
HRP20131083T1 true HRP20131083T1 (hr) 2013-12-20

Family

ID=40262072

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131083AT HRP20131083T1 (hr) 2007-11-08 2008-11-07 POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI

Country Status (18)

Country Link
US (1) US7968543B2 (enExample)
EP (2) EP2596795A1 (enExample)
JP (2) JP5645667B2 (enExample)
KR (2) KR101578481B1 (enExample)
CN (1) CN101835472A (enExample)
AR (1) AR069244A1 (enExample)
AU (1) AU2008325141B2 (enExample)
CA (1) CA2696807C (enExample)
CY (1) CY1114853T1 (enExample)
DK (1) DK2205244T3 (enExample)
ES (1) ES2436266T3 (enExample)
HR (1) HRP20131083T1 (enExample)
MX (1) MX2010002396A (enExample)
PL (1) PL2205244T3 (enExample)
PT (1) PT2205244E (enExample)
SI (1) SI2205244T1 (enExample)
TW (1) TW200924756A (enExample)
WO (1) WO2009061446A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001892B1 (en) * 2006-03-17 2013-04-24 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of proliferative diseases
CN101868465B (zh) 2007-09-19 2013-12-25 埃姆比特生物科学公司 包含N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲的固体形式、其组合物及其应用
SG174419A1 (en) 2009-03-23 2011-11-28 Ambit Biosciences Corp Methods of treatment using combination therapy
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
EP3150612A1 (en) 2009-11-05 2017-04-05 Ambit Biosciences Corporation Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
KR102769649B1 (ko) 2014-12-22 2025-02-19 젠자임 코포레이션 포유류 세포의 배양 방법
CN107427501B (zh) 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
WO2016143896A1 (ja) * 2015-03-11 2016-09-15 国立研究開発法人理化学研究所 難治性白血病治療薬
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021180008A1 (zh) * 2020-03-11 2021-09-16 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US233903A (en) * 1880-11-02 Velocipede
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
EP2001892B1 (en) 2006-03-17 2013-04-24 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of proliferative diseases
CN101868465B (zh) * 2007-09-19 2013-12-25 埃姆比特生物科学公司 包含N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲的固体形式、其组合物及其应用

Also Published As

Publication number Publication date
ES2436266T3 (es) 2013-12-30
WO2009061446A1 (en) 2009-05-14
US20090123418A1 (en) 2009-05-14
PT2205244E (pt) 2013-11-26
JP2014221765A (ja) 2014-11-27
AU2008325141A1 (en) 2009-05-14
JP5645667B2 (ja) 2014-12-24
EP2596795A1 (en) 2013-05-29
US7968543B2 (en) 2011-06-28
SI2205244T1 (sl) 2013-12-31
AR069244A1 (es) 2010-01-06
CY1114853T1 (el) 2016-12-14
EP2205244B1 (en) 2013-08-21
AU2008325141B2 (en) 2014-03-20
KR20150105494A (ko) 2015-09-16
EP2205244A1 (en) 2010-07-14
KR20100075853A (ko) 2010-07-05
PL2205244T3 (pl) 2014-01-31
CN101835472A (zh) 2010-09-15
CA2696807C (en) 2017-11-28
TW200924756A (en) 2009-06-16
JP2011503063A (ja) 2011-01-27
MX2010002396A (es) 2010-04-01
DK2205244T3 (da) 2013-11-25
CA2696807A1 (en) 2009-05-14
KR101578481B1 (ko) 2015-12-17

Similar Documents

Publication Publication Date Title
HRP20131083T1 (hr) POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI
AU2005215775B2 (en) Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
JP5774850B2 (ja) タペンタドール組成物
US20090306051A1 (en) Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
US20060240043A1 (en) Methods and compositions for treating migraine pain
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
BRPI0415649A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2019516733A5 (enExample)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2021080296A5 (enExample)
JP2015519329A5 (enExample)
HRP20191029T1 (hr) Derivati morfinana radi liječenja predoziranja lijekom
BRPI0614792A2 (pt) associação de um agente hipnótico com duração de ação longa e de um agente hipnótico com duração de ação curta e sua aplicação terapêutica
JP2018507243A5 (enExample)
CN110402140A (zh) 加波沙朵在治疗耳鸣中的用途
HRP20241457T1 (hr) Sredstva za degradaciju porodice cinkovih prstiju ikaros i njihova uporaba
JP2018522920A5 (enExample)
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
JP2016505050A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
RU2011101771A (ru) Педиатрические композиции для лечения рассеянного склероза
ES2985064T3 (es) Composición que comprende metilfenidato y ondansetrón para su uso en trastornos relacionados con la toxicomanía
JP2008534663A (ja) 慢性的な痛みおよび疲労を特徴とする症候群の治療のためのネフォパムおよびその類似体の使用